Aclaris Therapeutics (ACRS) Research & Development (2014 - 2026)
Aclaris Therapeutics' Research & Development came in at $18.07 million for Q2 2026, up 57.8% from $11.45 million a year earlier and up 15.4% from the prior quarter.
Aclaris Therapeutics (ACRS) Research & Development (2014 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Aclaris Therapeutics reported Research & Development of $63.34 million, up 66.6% year-over-year; for FY2025, it came in at $52.65 million, up 56.7% from FY2024.
- Research & Development carries a five-year compound annual growth rate of 12.4% (FY2020 to FY2025).
- Going back by year, Research & Development was $33.59 million in FY2024 (-65.9%), $98.38 million in FY2023 (+26.4%), $77.81 million in FY2022 (+77.6%) and $43.81 million in FY2021 (+49.3%).
- The Q2 2026 figure represents the highest quarterly Research & Development since Q4 2023.
- Year-over-year, Research & Development has increased for six consecutive quarters, with growth averaging 25.3% over the last eight quarters.
- The fastest year-over-year change in Research & Development over five years came in Q2 2022 (growth of 137.8%), and the weakest in Q3 2024 (a decline of 75.1%).
- Business Quant data shows ACRS's Research & Development at $15.66 million (Q1 2026), $16.58 million (Q4 2025) and $13.03 million (Q3 2025) in the three quarters before Q2 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Aclaris Therapeutics | 759.25 Mn | 759.25 Mn | 1.41 Mn | 18.07 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.07 Mn |
| Mar 31, 2026 | 15.66 Mn |
| Dec 31, 2025 | 16.58 Mn |
| Sep 30, 2025 | 13.03 Mn |
| Jun 30, 2025 | 11.45 Mn |
| Mar 31, 2025 | 11.58 Mn |
| Dec 31, 2024 | 9.03 Mn |
| Sep 30, 2024 | 5.96 Mn |
| Jun 30, 2024 | 8.76 Mn |
| Mar 31, 2024 | 9.85 Mn |
| Dec 31, 2023 | 26.65 Mn |
| Sep 30, 2023 | 23.88 Mn |
| Jun 30, 2023 | 25.28 Mn |
| Mar 31, 2023 | 22.59 Mn |
| Dec 31, 2022 | 21.07 Mn |
| Sep 30, 2022 | 23.66 Mn |
| Jun 30, 2022 | 18.78 Mn |
| Mar 31, 2022 | 14.31 Mn |
| Dec 31, 2021 | 14.10 Mn |
| Sep 30, 2021 | 13.98 Mn |
Aclaris Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ACRS&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ACRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ACRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();